A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells
- PMID: 10910062
A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells
Abstract
The microbially derived antiproliferative agent rapamycin inhibits cell growth by interfering with the signaling functions of the mammalian target of rapamycin (mTOR). In this study, we demonstrate that interleukin-3 stimulation induces a wortmannin-sensitive increase in mTOR kinase activity in a myeloid progenitor cell line. The involvement of phosphoinositide 3'-kinase (PI3K) in the regulation of mTOR activity was further suggested by findings that mTOR was phosphorylated in vitro and in vivo by the PI3K-regulated protein kinase, AKT/PKB. Although AKT phosphorylated mTOR at two COOH-terminal sites (Thr2446 and Ser2448) in vitro, Ser2448 was the major phosphorylation site in insulin-stimulated or -activated AKT-expressing human embryonic kidney cells. Transient transfection assays with mTOR mutants bearing Ala substitutions at Ser2448 and/or Thr2446 indicated that AKT-dependent mTOR phosphorylation was not essential for either PHAS-I phosphorylation or p70S6K activation in HEK cells. However, a deletion of amino acids 2430-2450 in mTOR, which includes the potential AKT phosphorylation sites, significantly increased both the basal protein kinase activity and in vivo signaling functions of mTOR. These results demonstrate that mTOR is a direct target of the PI3K-AKT signaling pathway in mitogen-stimulated cells, and that the identified AKT phosphorylation sites are nested within a "repressor domain" that negatively regulates the catalytic activity of mTOR. Furthermore, the activation status of the PI3K-AKT pathway in cancer cells may be an important determinant of cellular sensitivity to the cytostatic effect of rapamycin.
Similar articles
-
Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.Cancer Res. 2005 Sep 1;65(17):7800-8. doi: 10.1158/0008-5472.CAN-04-4180. Cancer Res. 2005. PMID: 16140948
-
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.Oncogene. 2007 Aug 16;26(38):5606-14. doi: 10.1038/sj.onc.1210346. Epub 2007 Mar 12. Oncogene. 2007. PMID: 17353907
-
Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation.Biochem J. 1999 Dec 1;344 Pt 2(Pt 2):427-31. Biochem J. 1999. PMID: 10567225 Free PMC article.
-
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.Breast Cancer Res. 2004;6(5):219-24. doi: 10.1186/bcr927. Epub 2004 Aug 12. Breast Cancer Res. 2004. PMID: 15318929 Free PMC article. Review.
-
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Expert Opin Investig Drugs. 2010. PMID: 20569080 Review.
Cited by
-
Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival.Genes Dev. 2016 Jun 15;30(12):1383-8. doi: 10.1101/gad.279661.116. Genes Dev. 2016. PMID: 27340174 Free PMC article.
-
(13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism.Front Oncol. 2016 Jun 15;6:135. doi: 10.3389/fonc.2016.00135. eCollection 2016. Front Oncol. 2016. PMID: 27379200 Free PMC article.
-
Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells.Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3514-9. doi: 10.1073/pnas.0608510104. Epub 2007 Feb 20. Proc Natl Acad Sci U S A. 2007. PMID: 17360675 Free PMC article.
-
Akt-1 expression level regulates CNS precursors.J Neurosci. 2004 Sep 29;24(39):8531-41. doi: 10.1523/JNEUROSCI.1470-04.2004. J Neurosci. 2004. PMID: 15456827 Free PMC article.
-
Everolimus treatment downregulates renocortical cyclooxygenase-2 expression in the rat kidney.Br J Pharmacol. 2005 Aug;145(8):1112-22. doi: 10.1038/sj.bjp.0706259. Br J Pharmacol. 2005. PMID: 15937522 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Miscellaneous